Related Experiment Videos
[Atrial fibrillation and apoplexy--risks and prevention]
B G Koefoed1, A L Gulløv, P Petersen
1Københavns praktiserende laegers laboratorium, AFASAK 2 Center.
Nordisk Medicin
|June 1, 1996
Summary
Warfarin significantly reduces stroke risk in patients with non-valvular atrial fibrillation. It is recommended for individuals over 60, offering better protection against secondary strokes compared to aspirin.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Context:
- Chronic non-valvular atrial fibrillation (NVAF) carries a significant annual stroke risk of approximately 4.5%.
- Oral anticoagulants like warfarin have demonstrated substantial stroke risk reduction in NVAF patients.
- The efficacy of aspirin in stroke prevention for NVAF remains less definitively established.
Purpose:
- To evaluate the effectiveness of warfarin and aspirin in preventing ischemic stroke in patients with non-valvular atrial fibrillation.
- To identify key risk factors for stroke in this patient population.
- To provide evidence-based recommendations for stroke prevention strategies in NVAF.
Summary:
- Five controlled trials showed warfarin reduced annual stroke incidence by 68% to 1.4%.
- Aspirin's effect was inconsistent across trials, with risk reductions of 18% and 44%.
- Warfarin demonstrated superior efficacy in preventing secondary strokes after TIA or minor stroke, reducing risk from 12% to 4%, while aspirin had no significant effect.
Impact:
- Warfarin (INR 2.0-3.0) is recommended for stroke prevention in non-valvular atrial fibrillation patients over 60.
- Identified risk factors include advanced age, prior stroke/TIA, hypertension, and diabetes.
- Ongoing trials explore potentially simpler and safer alternatives to conventional warfarin therapy.